What was the market valuation of the US hormone replacement-therapy market in 2024?

The market valuation was $5.5 Billion in 2024. Read More

What is the projected market valuation for the US hormone replacement-therapy market by 2035?

The projected valuation for 2035 is $10.5 Billion. Read More

What is the expected CAGR for the US hormone replacement-therapy market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 6.05%. Read More

Which application segment had the highest valuation in 2024?

The Menopause Treatment segment had the highest valuation at $1.65 Billion in 2024. Read More

What is the projected valuation for the Hormonal Imbalance Treatment segment by 2035?

The projected valuation for the Hormonal Imbalance Treatment segment by 2035 is $2.1 Billion. Read More

Which hormone type is expected to dominate the market by 2035?

Estrogen is expected to dominate the market with a projected valuation of $3.15 Billion by 2035. Read More

What is the expected growth for the Injectable route of administration by 2035?

The Injectable route of administration is projected to grow to $2.0 Billion by 2035. Read More

Which end user segment is anticipated to have the highest valuation in 2035?

The Hospitals segment is anticipated to have the highest valuation at $4.1 Billion in 2035. Read More

Who are the key players in the US hormone replacement-therapy market?

Key players include AbbVie, Bayer, Pfizer, Mylan, Teva, HRA Pharma, Amgen, Novo Nordisk, and Eli Lilly. Read More

What is the projected growth for the Transgender Hormone Therapy segment by 2035?

The Transgender Hormone Therapy segment is projected to grow to $1.5 Billion by 2035. Read More

US Hormone Replacement Therapy Market

ID: MRFR/Pharma/13152-HCR

100 Pages

Vikita Thakur

Last Updated: April 24, 2026

US Hormone Replacement Therapy Market Research Report: Size, Share, Trend Analysis By Applications (Menopause Treatment, Hormonal Imbalance Treatment, Transgender Hormone Therapy, Age-Related Hormonal Decline), By Hormone Type (Estrogen, Testosterone, Progesterone, Thyroid Hormones), By Route of Administration (Oral, Transdermal, Injectable, Implantable) and By End Users (Hospitals, Outpatient Clinics, Home Care) - Growth Outlook & Industry Forecast 2025 To 2035

US Hormone Replacement Therapy Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.05%

2024 Market Size$ 5.5 Billion

2025 Market Size$ 5.83 Billion

2035 Market Size$ 10.5 Billion

Key Players

AbbVie

Bayer

Pfizer

Mylan

Teva

HRA Pharma

Trends

Personalized Treatment Approaches
Rise of Natural and Bioidentical Hormones
Regulatory Changes and Innovations

Opportunities

Advancements in Medical Technology
Growing Awareness of Hormonal Health
Aging Population and Increased Demand

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Application (USD Billion)
  1. 4.1.1 Menopause Treatment
  2. 4.1.2 Hormonal Imbalance Treatment
  3. 4.1.3 Transgender Hormone Therapy
  4. 4.1.4 Age-Related Hormonal Decline
2. 4.2 Industrial Automation & Equipment, BY Hormone Type (USD Billion)
  1. 4.2.1 Estrogen
  2. 4.2.2 Testosterone
  3. 4.2.3 Progesterone
  4. 4.2.4 Thyroid Hormones
3. 4.3 Industrial Automation & Equipment, BY Route of Administration (USD Billion)
  1. 4.3.1 Oral
  2. 4.3.2 Transdermal
  3. 4.3.3 Injectable
  4. 4.3.4 Implantable
4. 4.4 Industrial Automation & Equipment, BY End User (USD Billion)
  1. 4.4.1 Hospitals
  2. 4.4.2 Outpatient Clinics
  3. 4.4.3 Home Care
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AbbVie (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bayer (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Pfizer (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Mylan (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Teva (IL)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 HRA Pharma (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Amgen (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Novo Nordisk (DK)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Eli Lilly (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY APPLICATION
3. 6.3 US MARKET ANALYSIS BY HORMONE TYPE
4. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY APPLICATION, 2024 (% SHARE)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY APPLICATION, 2024 TO 2035 (USD Billion)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY HORMONE TYPE, 2024 (% SHARE)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY HORMONE TYPE, 2024 TO 2035 (USD Billion)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 (% SHARE)
19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.2.2 BY HORMONE TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY END USER, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Hormone Replacement Therapy Market Segmentation

US Hormone Replacement Therapy Market By Application (USD Billion, 2025-2035)

Menopause Treatment
Hormonal Imbalance Treatment
Transgender Hormone Therapy
Age-Related Hormonal Decline

US Hormone Replacement Therapy Market By Hormone Type (USD Billion, 2025-2035)

Estrogen
Testosterone
Progesterone
Thyroid Hormones

US Hormone Replacement Therapy Market By Route of Administration (USD Billion, 2025-2035)

Oral
Transdermal
Injectable
Implantable

US Hormone Replacement Therapy Market By End User (USD Billion, 2025-2035)

Hospitals
Outpatient Clinics
Home Care

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”